Article

Mutant <i>KRAS</i> dosage contributes to heterogeneity in lung cancer therapeutic response

2026-05-09

Abstract excerpt

Oncogenic KRAS mutations promote tumorigenesis by constitutive activation of multiple, well-characterised signalling pathways. However, there is significant heterogeneity across mutant KRAS tumours in terms of mutation present, mutant allele abundance and downstream signalling strength. It is unclear whether these variations can impact responses to specific therapies. Here, we demonstrate that ∼20% of lung adeno...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 27ea1d5c-f795-52b8-a54d-df502ad5a51c
DOI: 10.64898/2026.05.06.723208

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Mutant <i>KRAS</i> dosage contributes to heterogeneity in lung cancer therapeutic responseDOI 10.64898/2026.05.06.723208Read

Mutant Kras copy number defines metabolic reprogramming and therapeutic susceptibilities.Semantic proximity Read

Increased dosage of wild-type KRAS protein drives <i>KRAS</i> -mutant lung tumorigenesis and drug resistanceSemantic proximity Read

Genetic determinants of <i>EGFR</i> -Driven Lung Cancer Growth and Therapeutic Response <i>In Vivo</i>Semantic proximity Read

Comparative Analysis and Isoform-Specific Therapeutic Vulnerabilities of KRAS Mutations in Non-Small Cell Lung Cancer.Semantic proximity Read

Changes in the Transcriptome and Synthetic Lethal Dependencies Following <i>KRAS</i> Mutant Expression Reveal Profound Tissue-SpecificitySemantic proximity Read

Metabolic rewiring in mutant Kras lung cancer.Semantic proximity Read

Concomitant KRAS mutations attenuate sensitivity of non-small cell lung cancer cells to KRAS G12C inhibition.Semantic proximity Read

<i>KRAS</i> signalling in malignant pleural mesotheliomaSemantic proximity Read

The likelihood of heterogeneity or additional mutation in KRAS or associated oncogenes to compromise targeting of oncogenic KRAS G12CSemantic proximity Read

Transcriptional Dosage of Oncogenic KRAS Drives Lung Adenocarcinoma Cell States, Progression and MetastasisSemantic proximity Read

Coexistence of KRAS mutation with mutant but not wild-type EGFR predicts response to tyrosine-kinase inhibitors in human lung cancer.Semantic proximity Read

MEK inhibitor resistance in lung adenocarcinoma is associated with addiction to sustained ERK suppressionSemantic proximity Read